Mostrar el registro sencillo del ítem

dc.contributor.authorSantos García, Diego 
dc.contributor.authorYañez Baña, Rosa María 
dc.contributor.authorLABANDEIRA GUERRA, CARMEN MARIA 
dc.contributor.authorHernando, M. I. C.
dc.contributor.authorCabo López, Iria 
dc.contributor.authorPaz González, José Manuel 
dc.contributor.authorALONSO LOSADA, MARIA GEMA 
dc.contributor.authorPalmas, M. J. G.
dc.contributor.authorCORES BARTOLOME, CARLOS 
dc.contributor.authorMartínez Miró, Cristina
dc.date.accessioned2024-01-02T10:02:30Z
dc.date.available2024-01-02T10:02:30Z
dc.date.issued2021
dc.identifier.issn2075-4426
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/34442442es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/18443
dc.description.abstractBACKGROUND AND OBJECTIVE: Pain is a frequent and disabling symptom in Parkinson's disease (PD) patients. Our aim was to analyze the effectiveness of safinamide on pain in PD patients from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on NON-MOTOR symptoms in Parkinson s disease patients) study. MATERIAL AND METHODS: SAFINONMOTOR is a prospective open-label single-arm study conducted in five centers from Spain. In this analysis, a secondary objective of the study, the score in the KPPS (King s Parkinson s Disease Pain Scale) at V1 (baseline) and V4 (6 months +/- 1 month) were compared. Wilcoxon s rank sum test was performed to test the changes from V1 to V4. RESULTS: Forty-four (88%) out of 50 PD patients (age 68.5 +/- 9.12 years; 58% women; 6.4 +/- 5.1 years from diagnosis) completed the study. The KPPS total score was reduced by 43.6% (from 40.04 +/- 36.18 in V1 to 22.60 +/- 21.42 in V4; p < 0.0001). By domains, improvement was observed in musculoskeletal (-35.9%; p = 0.009), fluctuation-related (-51.7%; p = 0.020), nocturnal (-46.1%; p = 0.001), discoloration and/or edema/swelling (-50.4%; p = 0.009) and radicular pain (-40.1%; p = 0.048). A total of 21 adverse events in 11 patients (22%) were reported, five being severe, but not related to safinamide. CONCLUSION: Safinamide is well tolerated and improves pain in PD patients at 6 months. Future studies are necessary to analyze the possible beneficial effect of safinamide on pain in PD patients.
dc.language.isoen
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePain Improvement in Parkinson's Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
dc.typeJournal Articlees
dc.authorsophosGarcia, D. S.;Bana, R. Y.;Guerra, C. L.;Hernando, M. I. C.;Lopez, I. C.;Gonzalez, J. M. P.;Losada, M. G. A.;Palmas, M. J. G.;Bartolome, C. C.;Miro, C. M.
dc.identifier.doi10.3390/jpm11080798
dc.identifier.pmid34442442
dc.identifier.sophos47169
dc.issue.number8
dc.journal.titleJOURNAL OF PERSONALIZED MEDICINE
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de A Coruña - Complexo Hospitalario Universitario de A Coruña::Neuroloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Ourense, Verín e O Barco de Valdeorras - Complexo Hospitalario Universitario de Ourense::Neuroloxía
dc.organizationServizo Galego de Saúde::Áreas Sanitarias (A.S.)::Área Sanitaria de Pontevedra e O Salnés - Complexo Hospitalario Universitario de Pontevedra::Neuroloxía
dc.page.initial798
dc.relation.publisherversionhttps://mdpi-res.com/d_attachment/jpm/jpm-11-00798/article_deploy/jpm-11-00798.pdf?version=1629118625es
dc.rights.accessRightsopenAccess
dc.subject.keywordCHUACes
dc.subject.keywordCHUOes
dc.subject.keywordCHUPes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number11


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional